The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape
VEGFR and mTOR inhibitors are broadly used in metastatic renal cell carcinoma (mRCC) therapy, and sequential first-line pazopanib (VEGFR inhibitor) and second-line everolimus (mTOR inhibitor) is a standard treatment option. Nivolumab and lenvatinib/everolimus combination was recently approved in Eur...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
19 May 2017
|
| In: |
Future oncology
Year: 2017, Volume: 13, Issue: 17, Pages: 1463-1471 |
| ISSN: | 1744-8301 |
| DOI: | 10.2217/fon-2017-0083 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.2217/fon-2017-0083 Verlag, Volltext: https://www.futuremedicine.com/doi/10.2217/fon-2017-0083 
|
| Author Notes: | Peter J Goebell, Christian Doehn, Carsten Grüllich, Viktor Grünwald, Thomas Steiner, Rainer Ehneß & Manfred Welslau |
| Summary: | VEGFR and mTOR inhibitors are broadly used in metastatic renal cell carcinoma (mRCC) therapy, and sequential first-line pazopanib (VEGFR inhibitor) and second-line everolimus (mTOR inhibitor) is a standard treatment option. Nivolumab and lenvatinib/everolimus combination was recently approved in Europe for use in mRCC after previous therapy. Prospective routine data on sequential therapy including nivolumab and/or lenvatinib are missing. This is a prospective, noninterventional study, which evaluates the effectiveness, tolerability, safety and quality of life following 450 patients with mRCC starting either on pazopanib as first-line therapy or third-line everolimus plus/minus lenvatinib following nivolumab. Adults with histologically confirmed mRCC of any subtype, who have a life expectancy of at least 6 months, are eligible. |
|---|---|
| Item Description: | Gesehen am 07.09.2018 |
| Physical Description: | Online Resource |
| ISSN: | 1744-8301 |
| DOI: | 10.2217/fon-2017-0083 |